-
161
First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis
Published 2025-01-01Subjects: Get full text
Article -
162
Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report
Published 2025-01-01Subjects: Get full text
Article -
163
The potential of MRI radiomics based on extrapulmonary metastases in predicting EGFR mutations: a systematic review and meta-analysis
Published 2025-01-01Subjects: “…Non-small cell lung cancer…”
Get full text
Article -
164
Identification of prognostic biomarker of non-small cell lung cancer based on mitochondrial permeability transition-driven necrosis-related genes and determination of anti-tumor ef...
Published 2025-02-01Subjects: “…Non-small cell lung cancer…”
Get full text
Article -
165
The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients
Published 2024-01-01Subjects: Get full text
Article -
166
Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Published 2025-01-01Subjects: “…Advanced non-small cell lung cancer…”
Get full text
Article -
167
Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational stud...
Published 2025-02-01Subjects: “…RET fusion-positive non-small cell lung cancer…”
Get full text
Article -
168
The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC
Published 2025-01-01Subjects: Get full text
Article -
169
-
170
Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre
Published 2025-02-01Subjects: Get full text
Article -
171
-
172
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
Published 2025-01-01Subjects: “…Non-Small Cell Lung Cancer…”
Get full text
Article -
173
Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients
Published 2025-01-01Subjects: “…Non-small cell lung cancer…”
Get full text
Article -
174
High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models
Published 2025-01-01Subjects: Get full text
Article -
175
Postoperative radiotherapy improves survival in completely resected non-small cell lung cancer with pathologic N2 stage IIIA and positive lymph node count greater than one: a SEER-...
Published 2025-02-01Subjects: “…non-small cell lung cancer…”
Get full text
Article -
176
-
177
Comprehensive analysis pinpoints CCNA2 as a prognostic and immunological biomarker in non-small cell lung cancer
Published 2025-01-01Subjects: Get full text
Article -
178
CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
Published 2025-02-01Subjects: Get full text
Article -
179
-
180
[18F]FDG PET/CT versus [18F]FDG PET/MRI in staging of non-small cell lung cancer: a head-to-head comparative meta-analysis
Published 2025-01-01Subjects: Get full text
Article